Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Titel:
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Auteur:
Curigliano, G. Mueller, V. Borges, V. Hamilton, E. Hurvitz, S. Loi, S. Murthy, R. Okines, A. Paplomata, E. Cameron, D. Carey, L.A. Gelmon, K. Hortobagyi, G.N. Krop, I. Loibl, S. Pegram, M. Slamon, D. Ramos, J. Feng, W. Winer, E.